Journal of Antimicrobial Chemotherapy

Article	Citations
Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study	108
Impact of the COVID-19 pandemic on the surveillance, prevention and control of antimicrobial resistance: a global survey	94
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study	86
An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London	76
Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): results from a worldwide point prevalence survey in 69 countries	70
Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials	60
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection	60
Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital	58
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19	57
Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study	55
Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections	53
Oxazolidinones: mechanisms of resistance and mobile genetic elements involved	51
The changing epidemiology of carbapenemase-producingKlebsiella pneumoniaein Italy: toward polyclonal evolution with emergence of high-risk lineages	51
Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge	48
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial	44
Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections	40
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid	40
Consumption of antibiotics in the community, European Union/European Economic Area, 1997–2017	39
Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019	39
Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates	39
High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinicalNeisseria gonorrhoeaeisolates from 25 European countries, 2018	39
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia	37
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre	37
Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics	37
In vitrosusceptibility ofMycobacterium abscessuscomplex and feasibility of standardizing treatment regimens	36

Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile	36
Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge?	35
Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications	34
IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bactera	34
Impact of an antimicrobial stewardship programme on reducing broad-spectrum antibiotic use and its effect on carbapenem-resistantAcinetobacter baumannii(CRAb) in hospitals in Jordan	34
Antimicrobial-induced horizontal transfer of antimicrobial resistance genes in bacteria: a mini-review	34
Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society	33
Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)	33
Prevalence of antimicrobial resistance genes and its association with restricted antimicrobial use in food-producing animals: a systematic review and meta-analysis	33
Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing	33
Large diversity of linezolid-resistant isolates discovered in food-producing animals through linezolid selective monitoring in Belgium in 2019	32
Transferable Acinetobacter baumannii plasmid pDETAB2 encodes OXA-58 and NDM-1 and represents a new class of antibiotic resistance plasmids	32
Antibiotics and healthcare facility-associatedClostridioides difficileinfection: systematic review and meta-analysis 2020 update	32
An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa	32
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial	32
Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases	32
Do high MICs predict the outcome in invasive fusariosis?	32
Ganciclovir therapeutic drug monitoring in transplant recipients	31
In vitroactivity of the novel antifungal olorofim against dermatophytes and opportunistic moulds includingPenicilliumandTalaromycesspecies	30
Delamanid or pretomanid? A Solomonic judgement!	30
Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19	30
Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19)	30
One Health compartmental analysis of ESBL-producing Escherichia coli on Reunion Island reveals partitioning between humans and livestock	29
ESBL-producing strains isolated from imported cases of enteric fever in England and Wales reveal multiple chromosomal integrations of blaCTX-M-15 in XDR Salmonella Typhi	29
Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial	28
Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring	28
Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial	28
Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis	28
Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales	27
Important considerations regarding the widespread use of doxycycline chemoprophylaxis against sexually transmitted infections	27
Evolution of β-lactamase-mediated cefiderocol resistance	27
Class D β-lactamases	27
Management ofClostridioides difficileinfection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines	27
Prevalence and genomic analysis of ESBL-producingEscherichia coliin retail raw meats in Singapore	27
High percentage of the ceftriaxone-resistantNeisseria gonorrhoeaeFC428 clone among isolates from a single hospital in Hangzhou, China	27
Changing molecular epidemiology and characteristics of MRSA isolated from bloodstream infections: nationwide surveillance in Japan in 2019	27
Murepavadin antimicrobial activity against and resistance development in cystic fibrosis Pseudomonas aeruginosa isolates	27
Syndromic diagnostic testing: a new way to approach patient care in the treatment of infectious diseases	27
Spread of hypervirulent multidrug-resistant ST147 Klebsiella pneumoniae in patients with severe COVID-19: an observational study from Italy, 2020–21	27
Invasive candidiasis: current clinical challenges and unmet needs in adult populations	26
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa	26
Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting	26
A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections	26
In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates	25
Characterization of Klebsiella pneumoniae complex isolates from pigs and humans in farms in Thailand: population genomic structure, antibiotic resistance and virulence genes	25
In vitroactivity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli fro	25
Detection ofmcr-9-harbouring ESBL-producingSalmonellaNewport isolated from an outbreak in a large-animal teaching hospital in the USA	25
Outpatient parenteral antimicrobial therapy (OPAT) in the UK: findings from the BSAC National Outcomes Registry (2015–19)	25
An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones	25
Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014–	24

Novel tigecycline resistance gene cluster tnfxB3-tmexCD3-toprJ1b in Proteus spp. and Pseudomonas aeruginosa, co-existing with tet(X6) on an SXT/R391 integrative and	24
IS26cannot move alone	24
Defining the scope of the European Antimicrobial Resistance Surveillance network in Veterinary medicine (EARS-Vet): a bottom-up and One Health approach	24
Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK	24
Emergence of a multidrug resistance efflux pump with carbapenem resistance gene blaVIM-2 in a Pseudomonas putida megaplasmid of migratory bird origin	24
Genomic analysis of 600 vancomycin-resistant Enterococcus faecium reveals a high prevalence of ST80 and spread of similar vanA regions via IS1216E and plasmid transfer in diverse	24
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study	24
Effective antimicrobial combination in vivo treatment predicted with microcalorimetry screening	24
Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study	24
Rapid spread of critical priority carbapenemase-producing pathogens in companion animals: a One Health challenge for a post-pandemic world	23
Carbapenemase-producing Enterobacteriaceae in transplant patients	23
Epidemiology, clinical aspects, outcomes and prognostic factors associated with Trichosporon fungaemia: results of an international multicentre study carried out at 23 medical centres	23
Neisseria gonorrhoeaeSequence Typing for Antimicrobial Resistance (NG-STAR) clonal complexes are consistent with genomic phylogeny and provide simple nomenclature, rapid visualization and antim	23
Mechanisms of antibiotic resistance of Clostridioides difficile	23
Prevalence of RND efflux pump regulator variants associated with tigecycline resistance in carbapenem-resistant Acinetobacter baumannii from a worldwide survey	23
A review of remdesivir for COVID-19 in pregnancy and lactation	23
Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis	23
Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study	23
Occurrence of a plasmid co-carrying cfr(D) and poxtA2 linezolid resistance genes in Enterococcus faecalis and Enterococcus casseliflavus from porcine manure, Italy	22
Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients	22
Characterization and outcome of invasive infections due toPaecilomyces variotii: analysis of patients from the FungiScope® registry and literature reports	22
Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments	22
IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis	22
Novel SCCmec type XV (7A) and two pseudo-SCCmec variants in foodborne MRSA in China	21
EUCAST rapid antimicrobial susceptibility testing (RAST): analytical performance and impact on patient management	21
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2	21
Invasive infections withPurpureocillium lilacinum: clinical characteristics and outcome of 101 cases from FungiScope® and the literature	21
Characterization of novel ISAba1-bounded tet(X15)-bearing composite transposon Tn6866 in Acinetobacter variabilis	21
Comparative phylogenomics of ESBL-, AmpC- and carbapenemase-producing Klebsiella pneumoniae originating from companion animals and humans	21
Pyocin efficacy in a murine model of Pseudomonas aeruginosa sepsis	21
Identification of thresholds in relationships between specific antibiotic use and carbapenem-resistantAcinetobacter baumannii(CRAb) incidence rates in hospitalized patients in Jordan	21
Point prevalence survey of antibiotic use in hospitals in Latin American countries	21
Activity of cefepime/zidebactam (WCK 5222) against ‘problem’ antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory	20
Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial	20
A nationwide genomic study of clinical Klebsiella pneumoniae in Norway 2001–15: introduction and spread of ESBLs facilitated by clonal groups CG15 and CG307	20
When to change treatment of acute invasive aspergillosis: an expert viewpoint	20
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2in vitroandin vivo	20
Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation	20
Role of new antibiotics for KPC-producingKlebsiella pneumoniae	20
Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?	19
Impact of antibiotic timing on mortality from Gram-negative bacteraemia in an English district general hospital: the importance of getting it right every time	19
Short versus prolonged courses of antimicrobial therapy for patients with uncomplicated Pseudomonas aeruginosa bloodstream infection: a retrospective study	19
Molecular pathways to high-level azithromycin resistance in Neisseria gonorrhoeae	19
Phenotypic and genomic analysis reveals Riemerella anatipestifer as the potential reservoir of tet(X) variants	19
Emergence of a Neisseria gonorrhoeae clone with reduced cephalosporin susceptibility between 2014 and 2019 in Amsterdam, The Netherlands, revealed by genomic population analysis	19
Spread of ESC-, carbapenem- and colistin-resistant Escherichia coli clones and plasmids within and between food workers in Lebanon	19
Relevance of the Consensus Principles for Appropriate Antibiotic Prescribing in 2022	19
The impact of anti-mould prophylaxis onAspergillusPCR blood testing for the diagnosis of invasive aspergillosis	19
Antifungal activity of nikkomycin Z against Candida auris	19
Consumption of quinolones in the community, European Union/European Economic Area, 1997–2017	18
Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection ofEscherichia coli and Klebsiella pneumoniaeharbouring serine- and New Delhi metallo-β-lactamases	18
Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods	18
Local characteristics associated with higher prevalence of ESBL-producing Escherichia coli in community-acquired urinary tract infections: an observational, cross-sectional study	18
Global prevalence of resistance to macrolides inMycoplasma pneumoniae: a systematic review and meta-analysis	18
Comparative genomics of ESBL-producingEscherichia coli(ESBL-Ec) reveals a similar distribution of the 10 most prevalent ESBL-Ec clones and ESBL genes among human community faecal and extra-inte	18
Respiratory antibacterial prescribing in primary care and the COVID-19 pandemic in England, winter season 2020–21	18
Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model	18
Genetic features of the poxtA linezolid resistance gene in human enterococci from France	18
Two high-risk clones of carbapenemase-producing Klebsiella pneumoniae that cause infections in pets and are present in the environment of a veterinary referral hospital	18
Do specific antimicrobial stewardship interventions have an impact on carbapenem resistance in Gram-negative bacilli? A multicentre quasi-experimental ecological study: time-trend analysis and charact	18
Aminoglycoside-resistance gene signatures are predictive of aminoglycoside MICs for carbapenem-resistant Klebsiella pneumoniae	17
Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study	17
Identification of 16S rRNA mutations in Mycoplasma genitalium potentially associated with tetracycline resistance in vivo but not selected in vitro in M. genitalium and	17
Probability of pharmacological target attainment with flucloxacillin in Staphylococcus aureus bloodstream infection: a prospective cohort study of unbound plasma and individual MICs	17
Pritelivir for recurrent aciclovir-resistant herpes simplex virus 2 infections in immunocompromised patients	17
Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19	17
Re-engineering a mobile-CRISPR/Cas9 system for antimicrobial resistance gene curing and immunization inEscherichia coli	17
GyrB in silico mining in 27 151 global gonococcal genomes from 1928–2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and	17
The bla and mec families of β-lactam resistance genes in the genera Macrococcus, Mammaliicoccus and Staphylococcus: an in-depth analysis with emphasis on Macrococ	17
Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: findings from a national representative HIV drug resistance survey	17
In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii	17
Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones	17
In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases	17
The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections	17
Legionellaantibiotic susceptibility testing: is it time for international standardization and evidence-based guidance?	16
In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae	16
Cefepime-induced neurotoxicity: systematic review	16
Azithromycin in patients with COVID-19: a systematic review and meta-analysis	16
Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis	16
Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales	16

Levofloxacin pharmacodynamics against Stenotrophomonas maltophilia in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision	16
Consumption of tetracyclines, sulphonamides and trimethoprim, and other antibacterials in the community, European Union/European Economic Area, 1997–2017	16
The impact of digital interventions on antimicrobial stewardship in hospitals: a qualitative synthesis of systematic reviews	16
Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on haemodialysis	16
Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis	16
An outbreak of multiply antibiotic-resistant ST49:ST128:KL11:OCL8Acinetobacter baumanniiisolates at a Sydney hospital	16
Blood and intra-abdominal Candida spp. from a multicentre study conducted in Madrid using EUCAST: emergence of fluconazole resistance in Candida parapsilosis, low echinocandin resistance	16
Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation	16
Persistence of a multidrug-resistant worldwide-disseminated methicillin-resistant Staphylococcus epidermidis clone harbouring the cfr linezolid resistance gene in a French hospital with	16
VraCP regulates cell wall metabolism and antibiotic resistance in vancomycin-intermediateStaphylococcus aureusstrain Mu50	16
PrEP monitoring and HIV incidence after PrEP initiation in France: 2016–18 nationwide cohort study	16
Antibiotic use during pregnancy and the risk of preterm birth: a population-based Swedish cohort study	16
AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics	16
Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates	16
Evaluation of a diagnostic algorithm for rapid identification of Gram-negative species and detection of extended-spectrum β-lactamase and carbapenemase directly from blood cultures	16
Thiocillin and micrococcin exploit the ferrioxamine receptor of Pseudomonas aeruginosa for uptake	16
In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile	15
Loss of outer membrane protein A (OmpA) impairs the survival of Salmonella Typhimurium by inducing membrane damage in the presence of ceftazidime and meropenem	15
Limited phylogenetic overlap between fluoroquinolone-resistant Escherichia coli isolated on dairy farms and those causing bacteriuria in humans living in the same geographical region	15
Clonal relationship of tet(X4)-positive Escherichia coli ST761 isolates between animals and humans	15
Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules	15
What are the most effective community-based antimicrobial stewardship interventions in low- and middle-income countries? A narrative review	15
In vitroevolution of cefepime/zidebactam (WCK 5222) resistance inPseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact onin vivoefficacy	15
Variability in carbapenemase activity of intrinsic OxaAb (OXA-51-like) β-lactamase enzymes inAcinetobacter baumannii	15
Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino oligomers	15
Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB)	15
Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015–18	15
Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation	15
Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control	15
Emergence of VIM-producing Enterobacter cloacae complex in France between 2015 and 2018	15
Clinical characteristics and management of olecranon and prepatellar septic bursitis in a multicentre study	15
Redefining therapeutic success in HIV patients: an expert view	15
Liposomal amphotericin B—the present	15
Dalbavancin in Gram-positive periprosthetic joint infections	15
Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis	15
Salmonella enterica serovar Typhi H58 clone has been endemic in Zimbabwe from 2012 to 2019	15
Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: implications for susceptibility breakpoints	14
Inhibition of azole-resistant Aspergillus fumigatus biofilm at various formation stages by antifungal drugs, including olorofim	14
Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial	14
Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study	14
Dissemination of Klebsiella pneumoniae ST147 NDM-1 in Poland, 2015–19	14
Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19	14
Using a public database of Neisseria gonorrhoeae genomes to detect mutations associated with zoliflodacin resistance	14
Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)	14
Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses	14
Detection of the transferable tigecycline resistance gene tet(X4) in Escherichia coli from pigs in the United Kingdom	14
Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis	14
Antimicrobial peptide WAM-1: a promising antibacterial and anti-inflammatory drug against carbapenem-resistant Klebsiella pneumoniae	14
Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings	14
SARS-CoV-2 coinfection with additional respiratory virus does not predict severe disease: a retrospective cohort study	14
Consumption of macrolides, lincosamides and streptogramins in the community, European Union/European Economic Area, 1997–2017	14
Identification of a novel tetracycline resistance gene, tet(63), located on a multiresistance plasmid from Staphylococcus aureus	14
A systematic review of antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium in sub-Saharan Africa	14
The paradoxical in vivo activity of β-lactams against metallo-β-lactamase-producing Enterobacterales is not restricted to carbapenems	14
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales	14
Linezolid-resistant Enterococcus gallinarum isolate of swine origin carrying cfr, optrA and poxtA genes	14
The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids	14
Update on the epidemiology of healthcare-acquired bacterial infections: focus on complicated skin and skin structure infections	14
Clinical relevance of nasopharyngeal SARS-CoV-2 viral load reduction in outpatients with COVID-19	14
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV	14
Liposomal amphotericin B—the past	14
Pet husbandry as a risk factor for colonization or infection with MDR organisms: a systematic meta-analysis	14
Characterization of the novel optrA-carrying pseudo-compound transposon Tn7363 and an Inc18 plasmid carrying cfr(D) in Vagococcus lutrae	14
Characterization of the novel plasmid-encoded MBL gene blaAFM-1, integrated into a blaIMP-45-bearing transposon Tn6485e in a carbapenem-resistant Pseudomonas aeruginosa cli	14
Inhibition of d-alanylation of teichoic acids overcomes resistance of methicillin-resistant Staphylococcus aureus	14
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study	14
Quality appraisal of antibiotic consumption in the community, European Union/European Economic Area, 2009 and 2017	14
Systematic review on the association between respiratory virus real-time PCR cycle threshold values and clinical presentation or outcomes	14
Impact of pre-existing drug resistance on risk of virological failure in South Africa	14
Clinical and serological outcomes in patients treated with oral doxycycline for early neurosyphilis	13
Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV	13
EQUAL Score Scedosporiosis/Lomentosporiosis 2021: a European Confederation of Medical Mycology (ECMM) tool to quantify guideline adherence	13
Robotic Antimicrobial Susceptibility Platform (RASP): a next-generation approach to One Health surveillance of antimicrobial resistance	13
Selection and characterization of mutational resistance to aztreonam/avibactam in β-lactamase-producing Enterobacterales	13
Outbreak by KPC-62-producing ST307 Klebsiella pneumoniae isolates resistant to ceftazidime/avibactam and cefiderocol in a university hospital in Madrid, Spain	13
A national longitudinal study evaluating the activity of cefditoren and other antibiotics against non-susceptible Streptococcus pneumoniae strains during the period 2004–20 in Spain	13
Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)	13
A 12 year experience of colistin resistance in Klebsiella pneumoniae causing neonatal sepsis: two-component systems, efflux pumps, lipopolysaccharide modification and comparative phylogenomics	13
Transmission of Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae: the role of infection control	13
In vitro interactions within a biofilm containing three species found in bacterial vaginosis (BV) support the higher antimicrobial tolerance associated with BV recurrence	13
Relationship of TonB-dependent receptors with susceptibility to cefiderocol in clinical isolates of Pseudomonas aeruginosa	13
Emergence of a Salmonella enterica serovar Typhimurium ST34 isolate, CFSA629, carrying a novel mcr-1.19 variant cultured from egg in China	13
Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae	13
Clinical exposure–response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model	13
Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity	13
Resistance mechanisms and molecular epidemiology of Pseudomonas aeruginosa strains from patients with bronchiectasis	13
Do antibiotics cause mitochondrial and immune cell dysfunction? A literature review	13
Gepotidacin: a novel, oral, ‘first-in-class’ triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea	13
Added value of rapid respiratory syndromic testing at point of care versus central laboratory testing: a controlled clinical trial	13
Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients	13
Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019	13
Prevalence of colistin heteroresistance in carbapenem-resistant Pseudomonas aeruginosa and association with clinical outcomes in patients: an observational study	13
Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay	13
Interchangeability of periplasmic adaptor proteins AcrA and AcrE in forming functional efflux pumps with AcrD in Salmonella enterica serovar Typhimurium	13
In vitro activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD 2007–18)	13